Crescent Biopharma (CBIO) Assets Average (2014 - 2026)
Crescent Biopharma (CBIO) reported Assets Average of $219.7 million for Q1 2026, up 956.07% year-over-year from $20.8 million in Q1 2025, and up 16.08% on a QoQ basis from $189.3 million in Q4 2025.
Crescent Biopharma (CBIO) has 13 years of Assets Average data on file, last reported at $219.7 million in Q1 2026.
- Quarterly Assets Average rose 956.07% year-over-year to $219.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $219.7 million (up 956.07% YoY) and the FY2025 annual result came in at $138.0 million, up 240.91% from the prior year.
- Assets Average improved to $219.7 million in Q1 2026 per CBIO's latest filing, from $189.3 million in the prior quarter.
- Across five years, Assets Average topped out at $219.7 million in Q1 2026 and bottomed at $20.1 million in Q3 2024.
- The 5-year median for Assets Average is $60.4 million (2023), against an average of $75.4 million.
- The widest annual swing landed in 2024, when Assets Average slumped 65.12%; it then jumped 956.07% in 2026.
- Tracing CBIO's Assets Average over 5 years: stood at $53.9 million in 2022, then decreased by 8.59% to $49.3 million in 2023, then slumped by 47.91% to $25.7 million in 2024, then jumped by 637.72% to $189.3 million in 2025, then grew by 16.08% to $219.7 million in 2026.
- Per Business Quant, the three latest CBIO Assets Average figures stand at $219.7 million (Q1 2026), $189.3 million (Q4 2025), and $147.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 219.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 219.71 Mn |
| Dec 31, 2025 | 189.28 Mn |
| Sep 30, 2025 | 147.85 Mn |
| Jun 30, 2025 | 81.71 Mn |
| Mar 31, 2025 | 20.80 Mn |
| Dec 31, 2024 | 25.66 Mn |
| Sep 30, 2024 | 20.06 Mn |
| Jun 30, 2024 | 29.31 Mn |
| Mar 31, 2024 | 39.76 Mn |
| Dec 31, 2023 | 49.26 Mn |
| Sep 30, 2023 | 57.51 Mn |
| Jun 30, 2023 | 65.37 Mn |
| Mar 31, 2023 | 60.37 Mn |
| Dec 31, 2022 | 53.89 Mn |
| Sep 30, 2022 | 60.50 Mn |
| Jun 30, 2022 | 73.25 Mn |
| Mar 31, 2022 | 87.91 Mn |
| Dec 31, 2021 | 101.15 Mn |
| Sep 30, 2021 | 116.16 Mn |
| Jun 30, 2021 | 131.20 Mn |
| Mar 31, 2021 | 140.43 Mn |
| Dec 31, 2020 | 146.63 Mn |
| Sep 30, 2020 | 154.39 Mn |
| Jun 30, 2020 | 160.23 Mn |
| Mar 31, 2020 | 165.03 Mn |
| Dec 31, 2019 | 174.21 Mn |
| Sep 30, 2019 | 186.39 Mn |
| Jun 30, 2019 | 198.39 Mn |
| Mar 31, 2019 | 209.64 Mn |
| Dec 31, 2018 | 220.00 Mn |
| Sep 30, 2018 | 230.43 Mn |
| Jun 30, 2018 | 241.56 Mn |
| Mar 31, 2018 | 188.00 Mn |
| Dec 31, 2017 | 122.20 Mn |
| Sep 30, 2017 | 118.72 Mn |
| Jun 30, 2017 | 79.40 Mn |
| Mar 31, 2017 | 39.78 Mn |
| Dec 31, 2016 | 45.20 Mn |
| Sep 30, 2016 | 51.89 Mn |
| Jun 30, 2016 | 48.24 Mn |
| Mar 31, 2016 | 44.58 Mn |
| Dec 31, 2015 | 52.10 Mn |
| Sep 30, 2015 | 58.89 Mn |
| Jun 30, 2015 | 55.25 Mn |
| Mar 31, 2015 | 52.86 Mn |
| Dec 31, 2014 | 59.85 Mn |
| Sep 30, 2014 | 64.98 Mn |
| Jun 30, 2014 | 62.79 Mn |
| Mar 31, 2014 | 31.67 Mn |